Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.56 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.56 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5241361 | 0.91 | CYP24A1 (0.51) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL30714800 | 0.88 | ACHE (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL3875408 | 0.88 | ACHE (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL13039619 | 0.84 | DRD2 (0.60) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL4462617 | 0.84 | METAP1 (0.58) | CYP24A1CYP27A1CYP26A1CYP19A1HTR2A | |
| SCHEMBL630841 | 0.83 | ACHE (0.58) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL7271049 | 0.83 | CYP24A1 (0.56) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL13193349 | 0.81 | THRA (0.62) | CYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL22867686 | 0.81 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 | |
| SCHEMBL5753017 | 0.81 | CYP24A1 (0.55) | CYP24A1CYP27A1CYP26A1CYP19A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-01-04 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708353-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2364089-B1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9181191-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181191-B2 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2015-08-20 | — | — | US | disclosed |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | BIOGEN MA INC. | 2014-04-10 | — | — | US | disclosed |
| EP-0851862-A1 | 1(HETERO)ARYL-4-(CONDENSED THIAZOL-2-YLALKYL)-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF 5-HT1A-RECEPTOR MEDIATED DISORDERS | Pharmacia Italia S.p.A. (IT) | 1998-07-08 | — | — | EP | disclosed |
| WO-1997008159-A1 | 1(HETERO)ARYL-4-(CONDENSED THIAZOL-2-YLALKYL)-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF 5-HT1A-RECEPTOR MEDIATED DISORDERS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-03-06 | — | — | WO | disclosed |
| CN-1029960-C | Process for preparing chromanol derivatives having neuroprotective effect | PFIZER (US) | 1995-10-11 | — | — | CN | disclosed |
| US-5436255-A | Method of treating diseases susceptable to treatment by blocking NMDA-receptors | PFIZER INC. (US) | 1995-07-25 | — | — | US | disclosed |
| US-5356905-A | Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs | PFIZER INC. (US) | 1994-10-18 | — | — | US | disclosed |
| EP-0441506-B1 | Neuroprotective 3-piperidino-4-hydrosychroman derivatives | PFIZER (US) | 1994-07-20 | — | — | EP | disclosed |
| WO-1991012005-A1 | NEUROPROTECTIVE 3-PIPERIDINO-4-HYDROXYCHROMAN DERIVATIVES AND ANALOGS | PFIZER INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| CN-1053923-A | 3-piperidino-(1-position only)-4-hydroxy benzo dichloro-pyran derivative with neuroprotective | PFIZER (US) | 1991-08-21 | — | — | CN | disclosed |
| EP-0441506-A2 | Neuroprotective 3-piperidino-4-hydrosychroman derivatives | PFIZER INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-3954983-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS | RICHARDSON-MERRELL INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002356-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | CYP24A1 1594/4885CYP27A1 1199/4885CYP26A1 3735/4885 |
| US-20150232492-A1 | HETEROBICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR4 | CYP24A1 1594/4885CYP27A1 1199/4885CYP26A1 3735/4885 |
| US-20140100195-A1 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | CYP24A1 1594/4885CYP27A1 1199/4885CYP26A1 3735/4885 |
| US-10081646-B2 | Heterobicyclic sphingosine 1-phosphate analogs | S1PR1, S1PR2, S1PR4 | CYP24A1 1594/4885CYP27A1 1199/4885CYP26A1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.